Navigation Links
Production of 5-aminovaleric and glutaric acid by metabolically engineered microorganism
Date:12/20/2012

We use many different types of chemicals and plastics for the convenience of our everyday life. The current sources of these materials are provided from petrochemical industry, using fossil oil as a raw material. Due to our increased concerns on the environmental problems and fossil resource availability, there has been much interest in producing those chemicals and materials from renewable non-food biomass through biorefineries. For the development of biorefinery process, microorganisms have successfully been employed as the key biocatalysts to produce a wide range of chemicals, plastics, and fuels from renewable resources. However, the natural microorganisms without modification are not suitable for the efficient production of target products at industrial scale due to their poor metabolic performance. Thus, metabolic capacities of microorganisms have been improved to efficiently produce desired products, the performance of which is suitable for industrial production of such products. Optimization of microorganism for the efficient production of target bioproducts has been achieved by systems metabolic engineering, which allows metabolic engineering at the systems-level.

5-aminovalic acid (5AVA) is the precursor of valerolactam, a potential building block for producing nylon 5, and can potentially be used as a C5 platform chemical for synthesizing 5-hydroxyvaleric acid, glutaric acid, and 1,5-pentanediol. It has been reported that a small amount of 5AVA is accumulated in Pseudomonas putida that has impaired L-lysine catabolism since 5AVA is a natural metabolite of L-lysine catabolism in P. putida. However, direct fermentative production of 5AVA has not yet been demonstrated, which might have great potential to open market for C5 chemicals and plastics.

In the paper published in Metabolic Engineering, a Korean research team led by Distinguished Pr
'/>"/>

Contact: Lan Yoon
hlyoon@kaist.ac.kr
82-423-502-295
The Korea Advanced Institute of Science and Technology (KAIST)
Source:Eurekalert

Page: 1 2

Related biology news :

1. Reproduction and life span are intertwined
2. VTT wins European innovation prize for a new bio-oil production technique
3. Can algae-derived oils support large-scale, low-cost biofuels production?
4. U of Minn. receives $1.8 million grant for improving efficiencies in fuel and plastics production
5. Production of FRP components without release agents
6. CSHL-led team discovers new way in which plants control flower production
7. Agriculture & food production contribute up to 29 percent of global greenhouse gas emissions
8. EyeLock Inc. Brings High-Tech Iris Biometric Production to Texas
9. Brainy beverage: Study reveals how green tea boosts brain cell production to aid memory
10. Clemson plant pathologist working to raise cucurbit yields, lower production costs
11. New process doubles production of alternative fuel while slashing costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/8/2015)... LAKES , N.J. and NEW YORK ... Company) and Guidepoint today announced BD ... start-up healthcare companies with free access to Guidepoint,s expert ... several start-ups that are developing cutting-edge technologies to improve ... a dedicated Guidepoint research manager, each start-up entrepreneur will ...
(Date:7/7/2015)... -- Research and Markets ( ... "Capacitive Fingerprint Sensors Patent Landscape" report ... fingerprint sensing technology is the most reliable and ... developed. This patent landscape focuses on fingerprint sensors ... of capacitive fingerprint sensors is closely linked to ...
(Date:7/2/2015)... , June 25, 2015 ... the addition of the "Natural Language Processing ... (Recognition, IVR, OCR, Pattern & Image Recognition) - ... offering. The key vendors occupying the ... IBM Corporation, Microsoft Corporation, NetBase Solutions, SAS Institute ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
... target blood vessels in fat and cause them to ... a model for future weight-loss therapies, say University of ... by Randy Seeley, PhD, of UC,s Metabolic Diseases Institute, ... peptide experienced decreased food intake and significant fat loss. ...
... Iowa February 1, 2010 Efforts will begin this ... by 21 percent and begin the development of a 30-mile ... group of 14 chimpanzees facing extinction. Organizers of the Gishwati ... fund reforestation of 647 acres (262 hectares) in the Kinyenkanda ...
... our brains are a lot more chaotic than previously ... Neurobiologists at the University of Maryland have discovered ... previous understandings of the auditory cortex, which had suggested ... first study of the auditory cortex conducted using advanced ...
Cached Biology News:'Starving' fat suppresses appetite 2Rwanda's Forest of Hope to expand by 21 percent, begin corridor for endangered chimpanzees 2Rwanda's Forest of Hope to expand by 21 percent, begin corridor for endangered chimpanzees 3Seeing the brain hear reveals surprises about how sound is processed 2Seeing the brain hear reveals surprises about how sound is processed 3
(Date:7/30/2015)... ... July 30, 2015 , ... ... a field clinical study of its canine osteoarthritis stem cell product, currently under ... (Kansas City, KS) and will be marketed in the US by Aratana. This ...
(Date:7/30/2015)... 30, 2015   Senomyx , Inc. (NASDAQ: ... technologies to discover, develop, and commercialize novel flavor ingredients ... reported financial results for the second quarter 2015. ... we remain on track to achieve our commercial and ... Officer of the Company. "Since our last quarterly earnings ...
(Date:7/30/2015)... , July 30, 2015 Ascendis Pharma ... that applies its innovative TransCon technology to address ... results from a six-month Phase 2 study to ... Growth Hormone in 53 treatment-naïve, pre-pubertal children with ... are extremely pleased with the top-line results from ...
(Date:7/30/2015)... 2015  Discovery Laboratories, Inc. (Nasdaq: DSCO ... second $1.0M tranche under a previously awarded Phase ... at up to $3.0 million to support continued ... a potential medical countermeasure to mitigate acute and ... an initial $1.0 million under this grant in ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... NEW YORK, June 3 American Oriental,Bioengineering (NYSE: ... to make a private,offer, subject to market conditions ... aggregate liquidation preference of newly,issued convertible preferred stock. ... dividends quarterly in arrears, and will be,convertible upon ...
... June 3, 2008, TIME: ... Dr. Candace Kendle, Chairman and CEO Kendle (Nasdaq: ... Tuesday, June 3 at 9:30 a.m. Eastern Time to,discuss the acquisition ... to provide an update on second quarter,progress. A question and answer ...
... and world-leading scientific psychopharmacology expertise; supports Kendle ... growth in its early phase business, ... KNDL ), a,leading global full-service clinical research ... Clinical Research Corporation,(DecisionLine Clinical Services), a privately ...
Cached Biology Technology:American Oriental Bioengineering Announces Proposed Private Offering to Raise $125 Million via Convertible Preferred Stock 2Kendle to Host Conference Call and Webcast to Discuss DecisionLine Acquisition and Provide Update on Second Quarter Progress 2Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 2Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 3Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 4Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 5
... for automated bioresearch: Developed for a ... Based on decades of experience in ... for bioresearch • Holographic gratings for ... and ease-of-use • Pulsed Xenon lamp ...
... GenePix Pro is the industry standard microarray ... combination of imaging and analysis tools, visualizations, ... GenePix Pro is included with every GenePix ... from third-party scanners and all types of ...
... personal-sized Thermal Cycler is the ideal instrument for ... range of PCR applications. Get Applied ... Save lab space without sacrificing results. ... Industry-Standard PCR Technology You Can Afford ...
... Sigma-Genosys offers custom peptide synthesis with a ... to best fit your research needs. ... Yield: 2mg-1g Sequence Length: ... Biotin, Fluorescein, N-acetylation, C-amidation, phosphorylation, D-amino acids, ...
Biology Products: